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Abstract 39 
Background: Atopic eczema (AE) is a common skin problem that impairs quality of life and is 40 
associated with the development of other atopic diseases including asthma, food allergy and allergic 41 
rhinitis. AE treatment is a significant cost burden for healthcare providers. The purpose of the trial is 42 
to investigate whether daily application of emollients for the first year of life can prevent AE 43 
developing in high risk infants (first degree relative with asthma, AE or allergic rhinitis).  44 
Methods: This is a protocol for a pragmatic two-arm randomised controlled, multicentre trial. Up to 45 
1400 term infants at high risk of developing AE will be recruited through the community, primary 46 
and secondary care in England. Participating families will be randomised in a 1:1 ratio to receive 47 
general infant skin care advice, or general skin care advice plus emollients with advice to apply daily 48 
to the infant for the first year of life. Families will not be blinded to treatment allocation. The 49 
primary outcome will be a blinded assessment of AE at 24 months of age using the UK working party 50 
diagnostic criteria. Secondary outcomes are other definitions of AE, time to AE onset, severity of AE 51 
(EASI and POEM), presence of other allergic diseases including food allergy, asthma and have fever, 52 
allergic sensitisation, quality of life, cost effectiveness and safety of the emollients. Subgroup 53 
analyses are planned for the primary outcome according to filaggrin genotype and the number of 54 
first degree relatives with AE and other atopic diseases. Families will be followed up by online and 55 
postal questionnaire at 3, 6, 12, 18 months with a face-to-face visit at 24 months. Long term follow 56 
up until 60 months will be via annual questionnaires.  57 
Discussion: This trial will demonstrate whether skin barrier enhancement through daily emollient for 58 
the first year of life can prevent AE from developing in high risk infants. If effective, this simple and 59 
cheap intervention has the potential to result in significant cost savings for healthcare providers 60 
throughout the world by preventing AE and possibly other associated allergic diseases.   61 
Trial registration:  Registered on 25 July 2014 in ISRCTN registry (ISRCTN21528841). 62 
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Background 66 
Atopic eczema (syn. atopic dermatitis or eczema)(1) is a very common chronic skin problem affecting 67 
16% to 30% of UK children and around 20% worldwide(2, 3). Atopic eczema usually starts in infancy 68 
and around 40% of cases persist into adulthood, especially those with early onset and widespread 69 
disease(4). The family impact of caring for a child with moderate or severe atopic eczema is greater 70 
than that in caring for children with type 1 diabetes mellitus, mainly due to sleep deprivation, 71 
employment loss, time to care for atopic eczema and financial costs(5).  72 
Children with atopic eczema, especially those with severe disease, are at increased risk of also 73 
developing other allergic (immunoglobulin E (IgE)-mediated) diseases including food allergy, allergic 74 
asthma and allergic rhinitis (hay fever)(6-8).  Eczema is often the first manifestation of the so-called 75 
“atopic march”, in which a child progresses from atopic eczema to food allergy, asthma and allergic 76 
rhinitis later in life (9, 10). Together these atopic diseases are the most common chronic diseases of 77 
childhood and represent a major financial burden to the UK National Health Service (NHS), with 78 
direct costs estimated at over £1 billion per annum in 2004(11). There is a strong association 79 
between atopic eczema during infancy and the risk of food allergy, with the highest prevalence of 80 
food allergy reported in early-onset and severe atopic eczema. A causal link has been proposed(12), 81 
and this is supported by evidence from mouse and human studies showing that sensitisation to 82 
some foods can occur across a defective skin barrier(13, 14). 83 
Atopic eczema is highly heritable and shows strong familial clustering. Prevalent mutations in the 84 
gene encoding filaggrin (FLG), a key skin barrier protein, represent the strongest and most consistent 85 
known genetic risk factor for atopic eczema(15, 16). 86 
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Emollient (moisturiser) therapy is intended to improve barrier function of the skin. An emollient 87 
provides lipids to the stratum corneum, which in turn, improves skin hydration by trapping water. 88 
Emollients also help to prevent inflammation caused by external irritants as evidenced by their 89 
benefit in preventing irritant occupational hand eczema(17). In premature babies, emollients have 90 
been shown to reduce the incidence of skin inflammation(18), and in people with atopic eczema, to 91 
reduce flares of atopic eczema (secondary prevention)(19). 92 
Primary prevention is a highly desirable goal in a complex chronic disease like atopic eczema with no 93 
cure. If primary prevention of atopic eczema using a strategy of early skin barrier enhancement with 94 
simple low-cost emollients is effective, it would represent a significant cost saving for healthcare 95 
providers through reduced treatment and appointment costs. Further cost savings would result if 96 
early skin barrier enhancement prevents sensitisation and associated food allergy, asthma or allergic 97 
rhinitis(11). Even if the frequency of atopic eczema cannot be significantly reduced, a shift in the 98 
severity distribution of atopic eczema towards milder cases could improve quality of life and reduce 99 
carer burden and healthcare provider costs.  100 
We carried out pilot studies to inform the design of this trial. A functional mechanistic study 101 
provided evidence for the choice of emollients for this trial and showed they are not associated with 102 
any harm to the skin barrier(20). A multicentre, randomised controlled pilot trial of 124 families 103 
showed families found the intervention acceptable and it would be feasible to conduct a larger trial 104 
of emollients for the prevention of atopic eczema(21). Clinical outcomes showed that infants in the 105 
emollient group had a significantly reduced risk of developing atopic eczema by 6 months of age 106 
compared to those in the control group (43% versus 22% respectively, relative risk, 0.50; 95% CI, 107 
0.28-0.90; P = .017). A further trial from Japan that included 118 infants showed similar results, with 108 
32% fewer infants in the emollient group developing atopic eczema(22). This large, pragmatic trial 109 
(the Barrier Enhancement for Eczema Prevention (BEEP) trial) described here is now required to 110 
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confirm the results seen in these small, short term trials and to establish the long term effects of 111 
emollients for preventing atopic eczema and associated allergic diseases.    112 
This is an abridged protocol based on protocol version 5.0 dated 26th October 2016. The full protocol 113 
is available on the trial website(23). This protocol adheres to the SPIRIT recommendations for 114 
interventional trials and the checklist is included (see additional file 1).  115 
Objectives 116 
 The main objective is to determine whether applying emollient daily to the entire body surface 117 
area for the first year of life can prevent atopic eczema in high risk children. 118 
 Other objectives are to investigate: 119 
o Whether emollients can delay the onset and/or reduce the severity in those who 120 
develop atopic eczema. 121 
o Whether emollients can prevent other allergic diseases developing. 122 
o The safety and cost effectiveness of the prevention strategy. 123 
o The role of FLG genotyping as possible stratifier of response to emollient intervention. 124 
Trial design 125 
This is a randomised, controlled, two-arm (skin care advice plus emollient versus skin care advice 126 
alone), parallel group, multicentre, assessor blind trial (Figure 1). It is a pragmatic design in which 127 
investigators have no scheduled contact with the families between randomisation and the 24 month 128 
visit in order to limit any influence on adherence, minimise the risk of un-blinding and keep the 129 
research nurse resources required to a reasonable level. All other contact is with the trial 130 
coordinating centre (figures 2 and 3). Screening for eligibility and the consent process is carried out 131 
either antenatally or shortly after delivery. Further eligibility checks are carried out post-delivery 132 
prior to randomisation which takes place within 3 weeks of delivery.  133 
7 
 
Setting 134 
The trial is recruiting families across England. Identification is via primary care (mailshot invitations 135 
to participate), secondary care (through antenatal care, dermatology clinics and posters), and in the 136 
community via direct advertising.  Recruiting sites are mainly secondary care centres, with a smaller 137 
number of primary care centres involved. A list of recruiting centres can be found in the 138 
acknowledgements.  139 
Participants 140 
Infants at high-risk of developing atopic eczema, defined as having a first degree relative with 141 
parent-reported doctor diagnosed atopic eczema, asthma or allergic rhinitis, are eligible for the trial. 142 
The infant must be no more than 21 days old at the point of randomisation, the mother must be 143 
aged at least 16 and the consenting adult must be able to understand English. Infants are not eligible 144 
if they are born prior to 37 weeks gestation, have a severe skin condition at time of randomisation 145 
that would make it difficult to assess the skin for signs of atopic eczema or that would preclude the 146 
use of emollients (such as dystrophic epidermolysis bullosa, ichthyosiform erythroderma or lamellar 147 
ichthyosis), or if they have a serious health issue that would make participation difficult for the 148 
family (e.g. neonatal sepsis or major congenital abnormalities). Only the first born of any multiple 149 
births will be randomised.  150 
Intervention 151 
Both groups receive general skin care advice to avoid soap and bubble bath, use mild cleansers and 152 
shampoos that have been specifically designed for babies, and avoid using baby wipes based on NICE 153 
guidance on infant skin care, July 2006(24). The use of bath oils is also discouraged unless directed to 154 
do so by a healthcare professional. Furthermore, the intervention group receives additional advice 155 
to apply emollient daily for the first year of life and are supplied with emollient free of charge. 156 
Parents are able to choose between Doublebase Gel® (Dermal Laboratories Ltd) and Diprobase 157 
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Cream® (Merck Sharp & Dohme Ltd.) and can switch emollient during the trial should they wish to. 158 
These emollients were chosen because they have a similar formulation to many emollient creams 159 
used in the UK, which would mean that the results of this trial would be applicable to a range of 160 
emollients with similar formulation and not restricted to the two emollients used in this trial. 161 
Emollients containing sodium lauryl sulphate (SLS) as an emulsifier were specifically excluded 162 
because they have been shown to have negative effects on the skin barrier(25). The skin care advice 163 
for both groups is sent to families within 2 days of randomisation in the form of a booklet and a 164 
short online video. These materials will be available as part of the final trial report.  165 
The intervention group advice includes how to apply the emollient; at least once daily all over the 166 
infant (the scalp can be avoided) and the emollient should always be applied bathing, even if it has 167 
previously been applied that day. Parents are advised to start the emollient as soon as possible after 168 
birth and definitely within 3 weeks and the start date of emollient usage is recorded by the trial 169 
coordinating centre during a routine 2 week post-randomisation phone call. Emollient is continued 170 
until the child is 1 year old and with parental reported usage collected at 3, 6 and 12 months. The 171 
trial coordinating centre keeps a record of the quantity of emollient provided to each participating 172 
family.  173 
If the infant develops skin problems during the trial, parents are advised to seek medical help in the 174 
usual way. Any eczema that develops will be treated as per normal practice regardless of treatment 175 
group allocation. 176 
Primary outcome 177 
The primary outcome is a diagnosis of atopic eczema at 24 months defined as meeting the UK 178 
Working Party Diagnostic Criteria for Atopic Eczema(26) which assesses signs and symptoms present 179 
over the past year. The criteria will be applied by a trained research nurse blinded to treatment 180 
allocation. Applying these criteria when the infants are 24 months old will detect atopic eczema that 181 
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has developed between the ages of 12 and 24 months and will therefore exclude transient 182 
eczematous rashes common in the first year of life that are often not true atopic eczema. Measuring 183 
the outcome at 24 months also ensures that any observed effect on reducing atopic eczema 184 
prevalence is a true preventative effect rather than a treatment effect of the emollient caused by 185 
shifting those with mild atopic eczema into the subclinical range.  186 
Secondary outcomes 187 
The secondary outcomes relate to outcomes up to and including the 24 month time-point: 188 
1. Presence of atopic eczema between birth and 24 months defined as: 189 
a. Parental report of a clinical diagnosis of atopic eczema. 190 
b. Parental completion of UK Working Party Diagnostic Criteria for Atopic Eczema at 12 191 
and 24 months. 192 
2. Presence of visible atopic eczema at 24 months (assessed by a trained research nurse 193 
blinded to treatment allocation). 194 
3. Time to onset of atopic eczema: 195 
a. First parental report of a clinical diagnosis of atopic eczema. 196 
b. First topical corticosteroid and /or immunosuppressant prescription for atopic 197 
eczema. 198 
4. Severity of atopic eczema: 199 
a. EASI at 24 months and 200 
b. POEM at 12 and 24 months. 201 
EASI and POEM are the core outcome instruments recommended by the Harmonising 202 
Outcome Measures for Eczema (HOME) for measuring clinician-reported signs and patient-203 
reported symptoms respectively(27, 28) and are both well-validated(29, 30). The EASI will be 204 
completed by a trained research nurse who is blinded to treatment allocation.  205 
5. Presence of other allergic diseases: 206 
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a. Parental reported wheezing, allergic rhinitis and food allergy symptoms, and 207 
parental report of a clinical diagnosis of food allergy between 12 and 24 months.   208 
b. Allergic sensitisation at 24 months to any of the following common allergens: milk, 209 
egg, peanut, cat, grass pollen, house dust mite. 210 
c. Confirmed diagnosis of food allergy at 24 months to milk, egg, and/or peanut 211 
derived from a combination of parental report, allergic sensitisation and (if required) 212 
food challenge. 213 
6. Health-related quality of life: 214 
a. Child quality of life using CHU-9D at 24 months. 215 
b. Parental quality of life measured using the EQ-5D-5L at baseline and 24 months.  216 
7. Health economic outcomes: 217 
a. Disease-related health care resource use. 218 
b. Cost effectiveness and cost-utility at 24 months (combining health resource use and 219 
health-related quality of life outcomes). If significantly more effective than usual 220 
care at 24 months, a longer term economic model from birth to 16 years we be 221 
developed. 222 
Safety outcomes 223 
Safety of the emollient determined from the number of skin infections and infant slippage incidents 224 
related to emollient use during the intervention period.  225 
Tertiary outcomes 226 
1. Parental opinion that their child has atopic eczema at any point during the trial. 227 
Data on tertiary outcomes 2-5 are collected at 36, 48 and 60 months: 228 
2. Parental report of a clinical diagnosis of atopic eczema. 229 
3. Severity of atopic eczema (POEM) 230 
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4. Presence of other atopic diseases: 231 
a. Parental reported wheezing, allergic rhinitis and food allergy symptoms. 232 
b. Parental report of a clinical diagnosis of asthma, allergic rhinitis or food allergy.  233 
c. Health-related quality of life (child; CHU-9D and parent; EQ-5D-5L).  234 
5. Health economic outcomes: 235 
a. Disease-related health care resource use. 236 
b. Cost effectiveness and cost-utility (combining health resource use and health-237 
related quality of life outcomes). 238 
 239 
Randomisation, allocation concealment and blinding 240 
The randomisation schedule (1:1 ratio) is based on a computer generated pseudo-random code 241 
using random permuted blocks of randomly varying size. It was created by the Nottingham Clinical 242 
Trials Unit (NCTU) and is held on a secure University of Nottingham server. During the trial, access to 243 
the sequence is confined to the IT programmer at NCTU. Randomisation is stratified by recruiting 244 
centre and number of immediate family members (parents or siblings) with atopic disease (1, 2, or 245 
more than 2). Recruiting centre staff randomise participants via a web-based randomisation system 246 
developed and maintained by NCTU. Recruiting centre staff are not sent the results of the 247 
randomisation. It is not possible to blind parents as to which group they are in, but the trial nurses 248 
conducting the skin examination at the 2 year visit are blinded to treatment allocation.  249 
Study procedures and data collection  250 
The screening and consent visit take place either in the family home or at the recruiting site, 251 
depending on parent preference, and consent obtained by the trial nurse (Figures 2 and 3). Separate 252 
optional consent is obtained for the FLG genotyping, skin prick testing and food challenges. 253 
Randomisation takes place after the infant is born and post-birth eligibility checks are completed. 254 
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Parents are sent questionnaires online (or paper if requested) at 3, 6, 12, 18, 36, 48 and 60 months 255 
to collect outcome data. There is a second face-to-face visit with the trial nurse at 24 months, again 256 
in the family home or at the recruiting centre depending on parent preference. At this 24 month visit 257 
the blinded trial nurse conducts the skin examination for the diagnostic criteria and the EASI, 258 
completes the questionnaires, and (where consent is given) takes the saliva sample and carries out 259 
the skin prick test. A summary of the data collection can be found in table 1: The schedule of trial 260 
assessments. The trial nurses are fully trained in the diagnosis of atopic eczema and carrying out the 261 
EASI. 262 
Saliva samples are collected via the child spitting into a pot or swabs taken from the inside of the 263 
child’s cheek and sent to the Centre for Dermatology & Genetic Medicine, University of Dundee for 264 
DNA extraction by standard techniques and FLG genotyping for the most prevalent null mutations in 265 
the white European population (2282del4, R501X, S3247X, and R2447X) according to published 266 
protocols(31). The skin prick testing is carried out in line with the British Society for Allergy and 267 
Clinical Immunology procedures(32) and the following allergens are tested; grass pollen mix, dust 268 
mite and cat (Allergopharma, Germany), peanut (Inmunotek, Spain), fresh skimmed cow’s milk and 269 
fresh chicken egg. Positive (1% histamine) and negative (0.9% saline) controls will also be used 270 
(Allergopharma, Germany). The trial nurses are fully trained in conducting skin prick tests and 271 
emergency procedures in the highly unlikely event of any serious allergic reactions.  Participants with 272 
a positive skin prick test or history suggestive for food allergy in whom further investigation is 273 
required for a diagnosis of food allergy to be made are invited for a supervised oral food challenge 274 
conducted by experienced allergy nurses following standard procedures who are blinded to 275 
treatment allocation. The presence of a clinical reaction is determined using modified PRACTALL and 276 
iFAAM criteria(33, 34). 277 
A methodological two-by-two factorial sub-study is nested within this trial to investigate the 278 
effectiveness of interventions designed to improve rates of follow up data collection. The 279 
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interventions are SMS text message notifications that the questionnaires will be sent by e-mail or 280 
post the following day versus no text message and the £10 inconvenience voucher either sent to 281 
parents either before the visit, or given at the 24 month visit. Full details can be found in the Studies 282 
Within a Trial (SWAT) registry(35).  283 
Small tokens of appreciation and birthday cards are sent to all participating families throughout the 284 
trial to promote retention, and the trial coordinating centre will make every effort to keep the 285 
parents contact details up to date throughout the trial. When questionnaires are not completed 286 
online or by post, families are telephoned by trial coordinating centre staff. Families wishing to 287 
withdraw from the intervention are encouraged to continue to provide data on the main outcomes, 288 
with particular importance placed on the 24 month face-to-face visit where the primary outcome 289 
data is collected. Where a face-to-face visit is not possible (e.g. the family have moved abroad) key 290 
outcomes are collected via remote means (e.g. telephone, text, email or post).  291 
 292 
Data will be entered directly onto the database by the trial nurses or parents via online 293 
questionnaires. All data are treated confidentially and held on a secure University of Nottingham 294 
server with restricted and password protected access. Questionnaires and other data collection 295 
forms will be available as part of the final trial report.  296 
Sample size calculation 297 
The sample size calculation was carried out using Stata(36, 37). A total of 1282 infants are required 298 
to detect a relative reduction of 30% in the intervention group in the number of infants who 299 
developed atopic eczema in the previous year (between 12 and 24 months of age) at the 5% 300 
significance level (2-sided) with 90% power based on an expected rate of 30% in the control group 301 
and allowing for 20% attrition at 24 months. This relative reduction is considered a conservative 302 
estimate; results of the pilot study showed a 50% reduction in atopic eczema at 6 months (43% 303 
developed atopic eczema in the control group (n = 55) compared to 22% in the emollient group (n = 304 
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53), 95% CI 0.28 to 0.9)(21). The effect size is anticipated to be lower in this main trial than in the 305 
pilot due to the more pragmatic trial design and the longer term outcome assessment.  306 
Recruitment began in November 2014 and ended in November 2016. A sample size review by the 307 
TSC took place after 21 months of recruitment to check the atopic eczema rate in the control group 308 
and attrition. As recruitment had progressed better than expected, the TSC advised that no 309 
additional families should be consented to the trial, but those who had already consented to the trial 310 
should continue to be randomised. The total number randomised at that point was expected to be 311 
approximately 1400.   312 
Planned analysis 313 
Analysis of the primary, secondary and safety outcomes will be performed when all the 24 month 314 
data have been collected. The longer term tertiary outcomes will be analysed once data collection is 315 
complete for the 60 month follow-up.  316 
The main approach to all analyses will be to analyse participants as randomised (intention-to-treat), 317 
regardless of adherence with allocation and without imputation for missing data. All analyses will be 318 
carried out using Stata/SE 13 or above(36). 319 
The primary outcome will be analysed using a generalised linear model adjusting for stratification 320 
variables. The difference between the two groups will be summarised using a relative risk with 95% 321 
confidence intervals.  Sensitivity analyses will be performed using multiple imputation for missing 322 
outcomes, by including any prognostic variables showing a baseline imbalance in the model and 323 
accounting for actual emollient use.  Analyses of secondary and long term outcomes will use 324 
appropriate regression models depending on the type of outcome and differences between the two 325 
groups summarised with 95% confidence intervals. Descriptive analysis of safety endpoints will be 326 
presented both according to randomised group and according to actual emollient use in the two 327 
groups. Planned subgroup analyses will be conducted by including an interaction term in the 328 
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regression analysis for the primary outcome according to: (i) whether an individual is FLG-wild type 329 
genotype or whether they have one or two of the screened FLG null mutations; (ii).the number of 330 
immediate family members with atopic disease; (iii) the number of immediate family members with 331 
atopic eczema.  332 
Full details of the analyses and potential sensitivity analyses for the food allergy/sensitization 333 
outcomes will be documented in the Statistical Analysis Plan prior to any analysis and made publicly 334 
available on the trial website(23).  335 
Economic evaluation 336 
Economic evaluations will be conducted to estimate the cost effectiveness of the intervention from 337 
an NHS perspective in the short term (24 months within trial analysis) medium term (60 months 338 
within trial analysis) and, if appropriate, longer term (birth to 16 years using a model-based analysis). 339 
For the within trial analyses, the incremental cost per atopic eczema case prevented, incremental 340 
cost per QALY based on CHU-9D (parental-proxy reported), and incremental cost per QALY based on 341 
main carer own health related Quality of life (EQ-5D-5L) will be estimated. An incremental cost-342 
effectiveness analysis will be performed using accepted methods with data reported in a 343 
disaggregated way(38-41). Analysis of uncertainty will follow recommended practice with results 344 
presented as cost-effectiveness acceptability curves(42, 43). If the intervention is significantly more 345 
effective at 24 months than normal practice, a longer term economic model taking an NHS 346 
perspective will be developed for the economic costs and benefits of the intervention for a single 347 
birth cohort from birth to 16 years using trial data, within-trial cost effectiveness analyses using data 348 
collected during the first 24 months and at 36, 48 and 60 months, other published data, expert 349 
opinion and population datasets (where appropriate and available).  350 
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Trial oversight 351 
Trial oversight is provided by the Trial Steering Committee (TSC) which comprises an independent 352 
chair, and three independent members (including one patient representative). Further details can be 353 
found in the acknowledgements. A separate data monitoring committee is not required due to the 354 
very low risk associated with the intervention, so this function will be covered by the TSC. 355 
Discussion 356 
This trial of up to 1400 infants at high-risk of developing atopic eczema will investigate whether 357 
daily, all over application of emollients (of a defined type of formulation) from birth for the first year 358 
of life can prevent atopic eczema developing by  2 years of age and whether any such preventive 359 
effects are maintained or are reduced up to the age of 5 years. It will also show whether the 360 
intervention can delay the onset of atopic eczema, or whether it alters the severity distribution 361 
towards milder disease. The effect on any other atopic conditions associated with atopic eczema 362 
(allergic rhinitis, asthma and food allergy) will also be assessed. By assessing the FLG genotype of 363 
participants, the extent to which any effect of emollients can be modified by filaggrin 364 
haploinsufficiency will also be determined. Any differential effect according to FLG genotype could 365 
be used for a personalised approach to future use of emollient for the prevention of atopic eczema.  366 
We have taken a pragmatic approach to all aspects of this trial including a limited number of 367 
exclusion criteria, interfering as little as possible in the use of the emollient, minimal follow up and 368 
an intention-to-treat analysis. However, as with all pragmatic trials, there are some limitations. 369 
Families participating in the trial are likely to be more motivated to use the emollients than the 370 
average population. Even so, we may observe a null result due to poor adherence because of the 371 
pragmatic nature of the advice to use emollients, whereas the intervention may be effective under 372 
conditions that enhances adherence. We have included only families whose child is at higher risk of 373 
developing eczema due to family history of atopy, although other groups are planning trials in 374 
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unselected for risk populations. Also, we have only offered two emollients in this trial, but there are 375 
many others commonly prescribed or purchased by parents. If the trial demonstrates that this 376 
relatively cheap and simple intervention is effective in preventing atopic eczema, uptake of the 377 
intervention will result in reduced costs for healthcare providers such as the UK National Health 378 
Service. Furthermore, if any effect is extended to prevention of other atopic conditions then the cost 379 
savings could be significantly greater.  380 
The results of the trial will be submitted for publication in peer-reviewed journals and the National 381 
Institute for Health Research (NIHR) journal series, and disseminated to healthcare providers and 382 
professional groups including health visitors, midwives, GPs, dermatologists and commissioners. 383 
Healthcare providers and professionals will then have the evidence required to make funding and 384 
healthcare decisions about emollients for preventing atopic eczema. We will inform all trial 385 
participants of the results of the main 2 year analysis and 5 year analysis and we will also post our 386 
results on the trial register. A variety of media outlets will be used to disseminate the results directly 387 
to pregnant women and new parents. Parents are often anxious to know whether their children will 388 
develop atopic eczema, especially those with experience of atopic eczema, and are keen to know 389 
what they can do minimise the risk. The results of this trial will help inform families whether 390 
emollients are an effective prevention strategy.  391 
Other trials of emollients and related interventions for the prevention of atopic eczema are being 392 
undertaken throughout the world, and we have formed a collaborative group to undertake a 393 
prospectively planned meta-analysis (PPMA) of such studies(44). Other investigators interested in 394 
collaborating in such a PPMA should contact this trial team directly. 395 
Current trial status 396 
Recruiting. 397 
18 
 
List of abbreviations 398 
AE – Atopic eczema 399 
BEEP – Barrier Enhancement for Eczema Prevention 400 
CHU-9D - Child Health Utility 9D 401 
CRN - Clinical Research Network 402 
EASI – Eczema Area and Severity Index 403 
EQ-5D-5L – Euroqol-5D-5L 404 
FLG - gene encoding filaggrin 405 
GP – General Practitioner 406 
HOME - Harmonising Outcome Measures for Eczema 407 
HTA – Health Technology Assessment 408 
NCTU - Nottingham Clinical Trials Unit 409 
NHS - National Health Service 410 
NICE – National Institute for Health and Care Excellence 411 
NIHR – National Institute for Health Research 412 
NRES - National Research Ethics Service 413 
POEM – Patient oriented eczema measure 414 
PPMA - Prospectively planned meta-analysis 415 
QALY - quality-adjusted life year  416 
19 
 
SWAT - Studies Within a Trial 417 
TSC – Trial Steering Committee 418 
UK DCTN - UK Dermatology Clinical Trials Network  419 
Declarations 420 
Ethical approval 421 
The trial was approved by the NRES Committee West Midlands (REC reference 14/WM/0162) on 9th 422 
June 2014 prior to the start of recruitment. This approval covered all trial sites. All parents give their 423 
full consent before being enrolled into the trial. If consent is given during pregnancy then it must be 424 
given by the mother, post-delivery the consent can be given by the mother or father.  425 
Consent for publication 426 
Not applicable 427 
Availability of data and material 428 
Not applicable 429 
Competing interests  430 
SJB has submitted a patent application (GB 1602011.7) relating to a mechanism for the gene EMSY in 431 
skin and has received honoraria for invited lectures at the American Academy of Asthma, Allergy and 432 
Immunology annual meetings.  433 
SL has received honorarium for educational activities from Thornton and Ross and Bayer. 434 
20 
 
M.J.C. has received fees for giving lectures and/or attending advisory boards and unrelated research 435 
funding from Almirall, Astellas Pharma, MSD, Johnson & Johnson and Stiefel-GSK who manufacture 436 
emollients. 437 
HCW became Director of the NIHR HTA Programme in October 2015. 438 
The other authors declare that they have no competing interests 439 
Funding 440 
This trial was funded by the National Institute for Health Research (NIHR) Health Technology 441 
Assessment (HTA) Programme (project number 12/67/12).  The food allergy and food sensitization 442 
assessments are funded by external grants from Goldman Sachs Gives (no reference number) and 443 
the Sheffield Children’s Hospital Research Fund (reference CA15008). Neither funder had any role in 444 
the trial design, the writing of this paper or decision to submit. 445 
The views and opinions expressed therein are those of the authors and do not necessarily reflect 446 
those of the HTA programme, NIHR, NHS or the Department of Health. 447 
Authors' contributions 448 
HCW conceived of the trial and is the chief investigator. JRC, RHH, EJM, KST, SJB, MR, SL, ELS, MJC, 449 
THS, LEB, AAM, and RJB contributed to the trial design. RHH and EJM co-ordinate the trial from the 450 
NCTU. AAM and LEB are responsible for statistical analysis. SJB designed the genetic study and is 451 
responsible for the analysis of samples and interpretation. MJC provided expertise on skin barrier 452 
function, emollients and skin care advice. THS leads the health economic aspects of the trial. RJB 453 
designed and leads on the sensitisation and food allergy assessments. JRC prepared the first draft of 454 
the manuscript. All authors commented on drafts of this manuscript, and read and approved the 455 
final manuscript.  456 
21 
 
Acknowledgements 457 
The trial was developed with and continues to be supported by the UK Dermatology Clinical Trials 458 
Network (UK DCTN). The UK DCTN is grateful to the British Association of Dermatologists and the 459 
University of Nottingham for financial support of the Network.  Additional nursing support is being 460 
been provided by the NIHR Clinical Research Networks. The trial is being managed through the 461 
Nottingham Clinical Trials Unit (NCTU) and sponsored by The University of Nottingham.  462 
Dr Nicola Jay (Consultant Paediatrician Respiratory and Allergy, Sheffield Children’s Hospital) and Dr 463 
Michael Perkin (Consultant in Paediatric Allergy, St. George’s, London) contributed significantly to 464 
developing the skin prick testing and food challenge aspects of trial.  465 
The trial management group are: JRC, RHH, EJM, KST, SJB, MR, SL, ELS, MJC, THS, LEB, AAM, RJB, 466 
HCW, plus Sarah Walker (Data coordinator NCTU) Jessica Haywood (Data administrator NCTU), 467 
Louisa Gray (Trial coordinator NCTU), and Andrew Jadowski (Trial administrator NCTU). The 468 
independent members of the trial steering committee are: Sarah Meredith, Chair, (Medical Research 469 
Council Clinical Trials Unit), Angela Crook (University College London), Paula Beattie (Royal Hospital 470 
for Sick Children, Glasgow), Kirsty Logan (patient representative, London). Michael Perkin (St. 471 
George’s, London) was previously an independent member of the TSC. Additional NCTU staff 472 
involved in the trial: Keith Whitaker (IT Programmer) Angela Pushpa-Rajah (Trial Manager Feb-Jul 473 
2015), Sandip Stapleton (Trial Manager Sept 15-July 2016) and Margherita Carucci (Trial Coordinator 474 
Oct 14-Aug 15). 475 
Recruiting centres are: Nottingham University Hospitals NHS Trust: Professor Hywel C. Williams (PI), 476 
Susan Davies-Jones, Professor Jim Thornton; Portsmouth Hospitals NHS Trust: Dr Bronwyn Hughes 477 
(PI), Andrew Gribbin, Sharon McCready, Zoe Garner, Amanda Hungate, Emma Glasspool, Rachel 478 
Watson, Ellie Jenkins; Harrogate and District NHS Foundation Trust Dr Alison Layton (PI), Louise 479 
Wills, Elizabeth Marshall, Joyce Guy, Christine Morgan; Sherwood Forest Hospitals NHS Foundation 480 
22 
 
Trust Dr Michael Yanney (PI), Caroline Moulds, Lisa Foster, Yvette Girvan, Tunde Solebo, Victoria 481 
Moore, Andrea Palfreman; Burton Hospitals NHS Foundation Trust Dr Mansoor Ahmed (PI) 482 
Stephanie Boswell, Claire Prince, Jane Radford, Clare Mewies, Claire Backhouse, Elizabeth Kemp; 483 
Derby Hospitals NHS Foundation Trust Dr Adam Ferguson (PI), Elaine Coulborn, Melody McGregor, 484 
Coral Smith, Vanessa Unsworth, SallyAnn Bell, Jill Smith, Liane Hufton; University Hospitals of 485 
Leicester NHS Trust Dr Karen Harman (PI), Dr Ingrid Helbling, Suzanne Foxon, Simal Patel; York 486 
Teaching Hospital NHS Foundation Trust Dr Calum Lyon (PI), Jill Green, Jessica Scott, Richard 487 
Furnival, Samantha Roche, Holly Alcock, Sian Sturdy; Sheffield Children’s NHS Foundation Trust 488 
Professor Michael Cork (PI) Heather Chisem, Hilary Rosser, Sarah Besley, Emma Steel, Sarah Senbeto, 489 
Pauline Bayliss, Carolyn Clark; Imperial College Healthcare NHS Trust Dr Robert Boyle (PI), Anna 490 
Bosanquet; Guy’s and St Thomas’ NHS Foundation Trust Dr Carsten Flohr (PI) Annette Briley, Claire 491 
Singh, Rebecca Williams, Shelley Carter, Elodie Lawley; Bristol Dr Matthew Ridd (PI), Kingsley Powell, 492 
Lyn Liddiard.  493 
Primary Care recruitment sites: Francis Grove Surgery Dr Katherine Broad (PI), Nina Walters, Sarah 494 
Buttinger, Rachel Joy; Streatham Common Practice Dr Kirsty Rankin (PI), Dr Ruth Danson, Ellen 495 
Trendell; Clapham Park Group Practice Dr Mydhili Chellappah (PI), Dr Dina Saleh; Park Group Practice 496 
Dr Mita Patel (PI), Jayshireen Singh; 497 
SJB is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science 498 
(106865/Z/15/Z). 499 
THS holds a Career Development Fellowship (NIHR-2014-07-006) supported by the National Institute 500 
for Health Research.  501 
References 502 
 503 
1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised 504 
nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the 505 
World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6. 506 
23 
 
2. Malik G, Tagiyeva N, Aucott L, McNeill G, Turner SW. Changing trends in asthma in 9-12 year 507 
olds between 1964 and 2009. Arch Dis Child. 2011;96(3):227-31. 508 
3. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in 509 
prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 510 
2009;124(6):1251-8 e23. 511 
4. Williams HC WB. Atopic dermatitis; The epidemiology, causes and prevention of atopic 512 
eczema Cambridge Univerity Press; 2000. 513 
5. Kemp AS. Cost of illness of atopic dermatitis in children: a societal perspective. 514 
Pharmacoeconomics. 2003;21(2):105-13. 515 
6. Martin PE, Eckert JK, Koplin JJ, Lowe AJ, Gurrin LC, Dharmage SC, et al. Which infants with 516 
eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy. 517 
2015;45(1):255-64. 518 
7. van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic 519 
eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565-9. 520 
8. von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindstrom CB, Svensson A. 521 
Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a 522 
prospective cohort. BMC Dermatol. 2012;12:11. 523 
9. Punekar YS, Sheikh A. Establishing the sequential progression of multiple allergic diagnoses 524 
in a UK birth cohort using the General Practice Research Database. Clin Exp Allergy. 525 
2009;39(12):1889-95. 526 
10. Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic 527 
rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3(2):67-73. 528 
11. Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: 529 
secondary analyses of national databases. Clin Exp Allergy. 2004;34(4):520-6. 530 
12. Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, et al. Does atopic dermatitis cause 531 
food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071-8. 532 
13. Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ, et al. Atopic dermatitis 533 
increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut 534 
allergy. J Allergy Clin Immunol. 2015;135(1):164-70. 535 
14. Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders SP, Mangan NE, et al. A 536 
homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen 537 
priming. Nat Genet. 2009;41(5):602-8. 538 
15. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic 539 
diseases. N Engl J Med. 2011;365(14):1315-27. 540 
16. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-541 
function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic 542 
dermatitis. Nat Genet. 2006;38(4):441-6. 543 
17. Williams C, Wilkinson SM, McShane P, Lewis J, Pennington D, Pierce S, et al. A double-blind, 544 
randomized study to assess the effectiveness of different moisturizers in preventing dermatitis 545 
induced by hand washing to simulate healthcare use. Br J Dermatol. 2010;162(5):1088-92. 546 
18. Edwards WH, Conner JM, Soll RF. The effect of prophylactic ointment therapy on nosocomial 547 
sepsis rates and skin integrity in infants with birth weights of 501 to 1000 g. Pediatrics. 548 
2004;113(5):1195-203. 549 
19. Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, Johannesson A, et al. Treatment with a 550 
barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and 551 
randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2009;23(11):1267-72. 552 
20. Danby SG, Chalmers J, Brown K, Williams HC, Cork MJ. A functional mechanistic study of the 553 
effect of emollients on the structure and function of the skin barrier. Br J Dermatol. 554 
2016;175(5):1011-9. 555 
24 
 
21. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, et al. Emollient 556 
enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy 557 
Clin Immunol. 2014;134(4):818-23. 558 
22. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of 559 
moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 560 
2014;134(4):824-30 e6. 561 
23. Centre of Evidence Based Dermatology. The BEEP Trial website  [cited 2017 17th March]. 562 
Available from: www.beepstudy.org. 563 
24. NICE. Postnatal care up to 8 weeks after birth  [cited 2017 17th March]. Available from: 564 
https://www.nice.org.uk/guidance/cg37. 565 
25. Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K, Cork MJ. The effect of aqueous cream 566 
BP on the skin barrier in volunteers with a previous history of atopic dermatitis. Br J Dermatol. 567 
2011;165(2):329-34. 568 
26. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria 569 
for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406-16. 570 
27. Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al. The Harmonising 571 
Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J 572 
Allergy Clin Immunol. 2014;134(4):800-7. 573 
28. Spuls PI, Gerbens LA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-574 
Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a 575 
Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2016. 576 
29. Gerbens LA, Prinsen CA, Chalmers JR, Drucker AM, von Kobyletzki LB, Limpens J, et al. 577 
Evaluation of the measurement properties of symptom measurement instruments for atopic 578 
eczema: a systematic review. Allergy. 2016. 579 
30. Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of 580 
clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 581 
2013;132(6):1337-47. 582 
31. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM, et al. 583 
Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in 584 
ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39(5):650-4. 585 
32. British Society for Allergy & Clinical Immunology (BSACI). Paediatric Skin Prick Testing  [cited 586 
2017 17th March]. Available from: 587 
http://www.bsaci.org/_literature_121183/Paediatric_skin_prick_testing_guideline. 588 
33. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al. 589 
Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, 590 
Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus 591 
report. J Allergy Clin Immunol. 2012;130(6):1260-74. 592 
34. Grabenhenrich LB, Reich A, Bellach J, Trendelenburg V, Sprikkelman AB, Roberts G, et al. A 593 
new framework for the documentation and interpretation of oral food challenges in population-594 
based and clinical research. Allergy. 2017;72(3):453-61. 595 
35. Barbarot S, Rogers NK, Abuabara K, Aubert H, Chalmers J, Flohr C, et al. Strategies used for 596 
measuring long-term control in atopic dermatitis trials: A systematic review. J Am Acad Dermatol. 597 
2016. 598 
36. StataCorp. CS, TX,. Stata Statistical Software: Release 13. 2013. Available from: 599 
http://www.stata.com. 600 
37. Fleiss J. L. LB, Paik M.C. Statistical Methods for Rates and Proportions. 3rd ed: Wiley; 2003. 601 
38. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness 602 
analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 603 
2015;18(2):161-72. 604 
39. Drummond M SM, Torrance G, O'Brien B, Stoddart G. . Methods for the economic evaluation 605 
of health care programmes. 4th ed: Oxford University Press; 2015. 606 
25 
 
40. Glick HA DJ, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials (Handbooks in Health 607 
Economic Evaluation). 2014. 608 
41. Evers S GM, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological 609 
quality of economic evaluations: Consensus on Health Economic Criteria. . International journal of 610 
technology assessment in health care. 2005;21(2):240-5. 611 
42. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its 612 
bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 613 
1997;6(4):327-40. 614 
43. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness 615 
acceptability curves. Health Econ. 2001;10(8):779-87. 616 
44. Robert Boyle HW, Lisa Askie, Karin Lodrup-Carlsen, Alan Montgomery, Joanne Chalmers, 617 
Naoki Shimojo, Maeve Kelleher, Emma Mead, . Prospectively planned meta-analysis of skin barrier 618 
studies for the prevention of eczema and associated health conditions. PROSPERO 619 
2017:CRD42017056965  [cited 2017 17th March]. Available from: 620 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017056965. 621 
 622 
Additional files 623 
Additional file 1 .docx 624 
Figure 1: Schematic diagram showing the trial design and duration for participating families 625 
Additional file 2 .docx 626 
Figure 2: Flowchart indicating participant flow through the trial 627 
Additional file 3 .docx 628 
Figure 3: Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure 629 
showing important events in the trial and their respective time points.  630 
 631 
Additional file 4 .docx 632 
Diagnostic criteria (UK Working Party Diagnostic Criteria for Atopic Dermatitis)  633 
Additional file 5 .docx 634 
Severity scale (EASI) 635 
Additional file 6 .docx 636 
Severity scale (POEM) 637 
 638 
 639 
Figure and table legends 640 
Figure 1: Schematic diagram showing the trial design and duration for participating families 641 
26 
 
Figure 2: Flowchart indicating participant flow through the trial 642 
Figure 3: Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure 643 
showing important events in the trial and their respective time points. 644 
 645 
 646 
 647 
